Age (years) |
51±2.4 |
47±5.4 |
0.49 |
Gender (male) - no.(%) |
31(76) |
6(67) |
0.58 |
Etiology – DCM - no.(%) |
30(73) |
3(33) |
0.02 |
QRS duration (ms) |
113±5.6 |
152±18 |
0.01 |
NYHA Class I - no.(%)* |
20(49) |
1(13) |
|
II - no.(%) |
17(41) |
4(50) |
0.03 |
III - no.(%) |
4(10) |
2(13) |
|
IV - no.(%) |
0 (0) |
1 (13) |
|
LVEF (%) |
39±2.2 |
39±4.7 |
0.91 |
Diabetes Mellitus - no.(%) |
2(5) |
0(0) |
0.50 |
Atrial fibrillation - no.(%) |
12(29) |
3(33) |
0.81 |
Syncope - no.(%) |
14(34) |
3(33) |
0.96 |
Amiodarone - no.(%) |
3(7) |
2(22) |
0.18 |
Beta blocker - no.(%) |
23(56) |
6(67) |
0.56 |
ACE/ARB - no.(%) |
26(63) |
7(78) |
0.41 |
Aldosterone antagonist - no.(%) |
7(17) |
0(0) |
0.18 |
R2I2 |
0.95±0.05 |
1.14±0.07 |
0.12 |
R2I2≥1.03 - no.(%) |
13(32) |
6(67) |
0.07 |
PERS |
1.13[0.62] |
1.46[0.49] |
0.22 |
PERS≥1.21 - no.(%) |
17(41) |
7(78) |
0.07 |
Negative R2I2+PERS - no.(%) |
17(41) |
0(0) |
|
Either R2I2/PERS - no.(%) |
18(44) |
5(56) |
0.01 |
Positive R2I2+PERS - no.(%) |
6(15) |
4(44) |
|
Follow up time (years) |
5.67[1.0] |
3.67[3.2] |
0.16 |